Versus hydroxychloroquine (DrugBank: Hydroxychloroquine)
3 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
46 | Malignant rheumatoid arthritis | 0 |
49 | Systemic lupus erythematosus | 1 |
95 | Autoimmune hepatitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00413361 (ClinicalTrials.gov) | June 2007 | 18/12/2006 | The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS | Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study | Systemic Lupus Erythematosus | Drug: versus hydroxychloroquine | Assistance Publique - Hôpitaux de Paris | Sanofi-Synthelabo | Completed | 18 Years | N/A | Both | 543 | Phase 4 | France |